 |
|
|
|
|
Ajinomoto, Tokyo, Japan
Ajinomoto is the world's largest producer of amino acids for pharmaceutical, cell culture and other applications. Ajinomoto has invested heavily in R&D in order to remain competitive in the production of amino acids and as a result has developed a number of technologies of interest in the development and manufacture of protein therapeutics including:
- Alanyl-Glutamine Dipeptide
Alanyl-glutamine is now available from Ajinomoto for use as an alternative source of L-Glutamine in mammalian cell culture. Although Alanyl-Glutamine is acknowledged to offer superior performance to L-Glutamine in cell culture, historically it has not been economically viable. Ajinomoto have developed a highly efficient biotransformation that makes the use of the dipeptide feasible.
- L-Arginine
Ajinomoto have identified that L-Arginine can be used to improve yields of MAb downstream purification by Protein A chromatography.
- Insulin-Like Growth Factor 1
Human Insulin is routinely used as a growth factor in mammalian cell culture but in fact the protein achieves its effect on cell growth through interaction with the IGF-1 receptor. Historically IGF-1 production has been inefficient even though it can be used in culture at concentrations 10-100fold less than Insulin. Ajinomoto have developed a highly efficient method for the expression and purification of IGF-1 and are making the protein available for use in cell culture applications.
Biothera, Minnesota, USA
Biothera are developing Imprime PGG as a cotherapy to enhance the biological and therapeutic efficacy of monoclonal antibodies (Mabs) in oncology. Imprime PGG is supported by extensive preclinical and clinical data and Phase II studies are being initiated in combination with marketed oncology Mabs.
Dompé pha.r.ma, L'Aquila, Italy
Dompe pha.r.ma are the R&D and Manufacturing division of Dompé Group, an Italian, fully-integrated Pharma/biotech company. Dompé pha.r.ma are interested in in-licensing or collaborative development opportunities based on protein therapeutics which are expressed in microbial expression systems. The company has a particular interest in oncology therapeutics.
Fleet BioProcessing, Hampshire, UK
Fleet BioProcessing specialize in the development of processes to optimize conjugation of small- and macromolecules to proteins, particularly antibodies. The company has its roots in the in vitro diagnostics market and as a result has experience of over 5000 antibody conjugations.
|
|
|
|
|
|
|
|
|
